Will Abbott Labs Help You Retire Rich?

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap. In this series, I look at 10 measures to show what makes a great retirement-oriented stock.

Until very recently, Abbott Labs (NYSE: ABT  ) was one of the biggest well-diversified players in the health-care space. Yet even with the company having completed its major spinoff, the continuing Abbott still has a wide array of different businesses. How will Abbott fare in its new form? Let's revisit how Abbott Labs does on our 10-point scale.

The right stocks for retirees
With decades to go before you need to tap your investments, you can take greater risks, weighing the chance of big losses against the potential for mind-blowing returns. But as retirement approaches, you no longer have the luxury of waiting out a downturn.

Sure, you still want good returns, but you also need to manage your risk and protect yourself against bear markets, which can maul your finances at the worst possible time. The right stocks combine both of these elements in a single investment.

When scrutinizing a stock, retirees should look for:

  • Size. Most retirees would rather not take a flyer on unproven businesses. Bigger companies may lack their smaller counterparts' growth potential, but they do offer greater security.
  • Consistency. While many investors look for fast-growing companies, conservative investors want to see steady, consistent gains in revenue, free cash flow, and other key metrics. Slow growth won't make headlines, but it will help prevent the kind of ugly surprises that suddenly torpedo a stock's share price.
  • Stock stability. Conservative retirement investors prefer investments that move less dramatically than typical stocks, and they particularly want to avoid big losses. These investments will give up some gains during bull markets, but they won't fall as far or as fast during bear markets. Beta measures volatility, but we also want a track record of solid performance as well.
  • Valuation. No one can afford to pay too much for a stock, even if its prospects are good. Using normalized earnings multiples helps smooth out one-time effects, giving you a longer-term context.
  • Dividends. Most of all, retirees look for stocks that can provide income through dividends. Retirees want healthy payouts now and consistent dividend growth over time -- as long as it doesn't jeopardize the company's financial health.

With those factors in mind, let's take a closer look at Abbott Labs.


What We Want to See


Pass or Fail?


Market cap > $10 billion

$54.5 billion



Revenue growth > 0% in at least four of five past years

5 years



Free cash flow growth > 0% in at least four of past five years

4 years


Stock stability

Beta < 0.9




Worst loss in past five years no greater than 20%




Normalized P/E < 18




Current yield > 2%




5-year dividend growth > 10%




Streak of dividend increases >= 10 years

0 years*



Payout ratio < 75%




Total score


7 out of 10

Source: S&P Capital IQ.
*Spinoff of AbbVie makes prior comparison not meaningful. Total score = number of passes.

Since we looked at Abbott Labs last year, the company lost a point, as the spinoff of AbbVie (NYSE: ABBV  ) resulted in a lower dividend. But the stock has performed well, rising about 20% over the past year after adjusting for the spun-off AbbVie.

After a long wait, Abbott finally broke itself into two pieces. AbbVie got the company's proprietary drug business, including blockbuster Humira, which has sales that amount to almost half of AbbVie's projected revenue. Abbott got to keep the rest of the business, which includes generic drugs, nutritional products, diagnostics, and vascular products.

In its first quarterly report as an independent company in January, Abbott reveled in being in what CFO Thomas Freyman called a "no-Humira world." Although its nutritional segment did well and its diagnostics business had a nice jump in revenue, Abbott's generic drug segment and vascular health unit didn't fare as well. In particular, nutritionals will be a key driver of performance for the new Abbott, and it's faring well in emerging markets such as China. By contrast, Mead Johnson Nutrition (NYSE: MJN  ) reported difficulties in China earlier last year.

Meanwhile, for generics, Abbott needs to focus on emerging markets as well. Increasingly, industry giants Teva Pharmaceutical (NYSE: TEVA  ) and Dr. Reddy's have moved toward emerging markets, with Teva in particular having found respite from falling U.S. sales by looking to faster-growing countries. The key is for Abbott to use generics as a way to break into new markets, and then once its name is better known, it can start selling higher-margin products.

For retirees and conservative investors, the new Abbott may seem like an unknown quantity. But despite some concerns about a lower yield, the company looks like a solid health-care pick for retirement portfolios.

Keep searching
Finding exactly the right stock to retire with is a tough task, but it's not impossible. Searching for the best candidates will help improve your investing skills, and teach you how to separate the right stocks from the risky ones.

If you're still confused about Abbott and AbbVie, we understand. To help investors better understand the situation, the Fool has created a brand new premium report on both stocks. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this report by clicking here now.

Add Abbott Labs to My Watchlist, which will aggregate our Foolish analysis on it and all your other stocks.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2303722, ~/Articles/ArticleHandler.aspx, 5/25/2016 9:13:25 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Caplinger

Dan Caplinger has been a contract writer for the Motley Fool since 2006. As the Fool's Director of Investment Planning, Dan oversees much of the personal-finance and investment-planning content published daily on With a background as an estate-planning attorney and independent financial consultant, Dan's articles are based on more than 20 years of experience from all angles of the financial world.

Today's Market

updated 11 hours ago Sponsored by:
DOW 17,706.05 213.12 0.00%
S&P 500 2,076.06 28.02 0.00%
NASD 4,861.06 95.27 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/24/2016 4:00 PM
ABT $37.98 Up +0.61 +0.00%
Abbott Laboratorie… CAPS Rating: ****
MJN $82.46 Up +0.28 +0.00%
Mead Johnson Nutri… CAPS Rating: ****
TEVA $51.89 Up +0.67 +0.00%
Teva Pharmaceutica… CAPS Rating: *****